Literature DB >> 15982350

Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study.

Per Ljungman1, Hareth Nahi, Annika Linde.   

Abstract

An open, randomised study was performed to determine whether two doses of influenza vaccine were more effective than one to elicit an immune response in 70 patients with haematological malignancies. The responses were not improved by two doses compared with one (influenza A virus serotypes H1/N1 18% vs. 22% and H3/N2 26% vs. 14%; influenza B 25% vs. 22%). The results were similar in patients with ongoing and discontinued therapy. Patients treated with monoclonal antibodies for lymphoma had very poor responses. We conclude that two doses of influenza vaccine do not improve the antibody response in patients with haematological malignancies.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15982350     DOI： 10.1111/j.1365-2141.2005.05582.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  35 in total

1.  Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Bilal Mohty; Michael Bel; Marija Vukicevic; Monika Nagy; Emmanuel Levrat; Sara Meier; Stephane Grillet; Christophe Combescure; Laurent Kaiser; Yves Chalandon; Jakob Passweg; Claire-Anne Siegrist; Eddy Roosnek
Journal:  Haematologica       Date:  2011-03-21       Impact factor: 9.941

2.  Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

Authors:  Davide Bedognetti; Gabriele Zoppoli; Carlotta Massucco; Elisa Zanardi; Simonetta Zupo; Andrea Bruzzone; Mario Roberto Sertoli; Enrico Balleari; Omar Racchi; Marco Messina; Graziano Caltabiano; Giancarlo Icardi; Paolo Durando; Francesco M Marincola; Francesco Boccardo; Manlio Ferrarini; Filippo Ansaldi; Andrea De Maria
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

3.  Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.

Authors:  Hugues de Lavallade; Paula Garland; Takuya Sekine; Katja Hoschler; David Marin; Kate Stringaris; Eva Loucaides; Katherine Howe; Richard Szydlo; Ed Kanfer; Donald Macdonald; Peter Kelleher; Nichola Cooper; Ahmad Khoder; Ian H Gabriel; Dragana Milojkovic; Jiri Pavlu; John M Goldman; Jane F Apperley; Katayoun Rezvani
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

4.  Ibrutinib may impair serological responses to influenza vaccination.

Authors:  Abby P Douglas; Jason A Trubiano; Ian Barr; Vivian Leung; Monica A Slavin; Constantine S Tam
Journal:  Haematologica       Date:  2017-06-28       Impact factor: 9.941

5.  Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.

Authors:  Andrew R Branagan; Eamon Duffy; Randy A Albrecht; Dennis L Cooper; Stuart Seropian; Terri L Parker; Geliang Gan; Fangyong Li; Daniel Zelterman; Chandra Sekhar Boddupalli; Lin Zhang; Rakesh Verma; Thomas M Ferencz; Madhav V Dhodapkar
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-03-07

Review 6.  Seasonal influenza vaccine in immunocompromised persons.

Authors:  Mohammad Bosaeed; Deepali Kumar
Journal:  Hum Vaccin Immunother       Date:  2018-03-21       Impact factor: 3.452

7.  Statement on Seasonal Influenza Vaccine for 2011-2012: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-10-14

8.  Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2010-2011: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-08-31

Review 9.  Immunization in Patients with Rheumatic Diseases: A Practical Guide for General Practitioners.

Authors:  Piyush Ranjan; Avinash Chakrawarty; Archana Kumari; Jitendra Kumar
Journal:  J Clin Diagn Res       Date:  2015-05-01

10.  Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy.

Authors:  Kei Nakashima; Masahiro Aoshima; Satoko Ohfuji; Kanzo Suzuki; Masahiro Katsurada; Naoko Katsurada; Masafumi Misawa; Yoshihito Otsuka; Kyoko Kondo; Yoshio Hirota
Journal:  Hum Vaccin Immunother       Date:  2016-11-07       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.